Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Clinical Equivalence Study of Mometasone Nasal Spray

ClinicalTrials.gov ID: NCT01850823

Public ClinicalTrials.gov record NCT01850823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Study identification

NCT ID
NCT01850823
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
880 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2013
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013
Last update posted
Aug 18, 2020

2013

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Investigator site 18 Stockbridge Georgia
Investigator site 1 Louisville Kentucky
Investigator site 3 Bethesda Maryland
Investigator Site 19 Minneapolis Minnesota
Investigator Site 24 St Louis Missouri
Investigator site 22 Bellevue Nebraska
Investigator Site 23 Skillman New Jersey
Investigator site 2 Corning New York
Investigator site 9 High Point North Carolina
Investigator site 20 Raleigh North Carolina
Investigator site 25 Cincinnati Ohio
Investigator site 21 Sylvania Ohio
Investigator site 16 Spartanburg South Carolina
Investigator Site 10 Austin Texas
Investigator Site 12 Austin Texas
Investigator site 6 Austin Texas
Investigator Site 11 Kerrville Texas
Investigator Site 7 New Braunfels Texas
Investigator Site 13 San Antonio Texas
Investigator site 14 San Antonio Texas
Investigator site 5 San Antonio Texas
Investigator site 8 San Antonio Texas
Investigator site 4 Waco Texas
Investigator Site 15 Draper Utah
Investigator Site 17 Greenfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01850823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2020 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01850823 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →